Table 2.

Overview of the experiments involving the use of differentiated MSCs in MS experimental models.

Age and Strain	MS Model	MSCs	Differentiation Method	MSCs Administration	Results	Ref.
6–7-week-old female C57BL/6 mice	MOG-EAE	Human and mouse BM-MSCs	DMEM-F12 supplemented with B-27, bFGF, EGF for 14 days	Intraventricularly 8 days after EAE induction	↑ disease score; ↓ inflammation, axonal loss, and demyelination	[60]
12-week-old female C57BL/6 mice	MOG-EAE	Mouse BM-MSCs	Neurobasal media supplemented with B27, insulin-transferring-selenite, L-glutamine, penicillin and streptomycin, bFGF and dehydroepiandrosterone	1 × 106; i.v. on days 22, 29, and 36 after immunization	↑ IL-10; ↓ proliferation of pathogenic MOG35-55-specific T cells, IFN-γ production	[61]
8–10-week-old female C57BL/6 mice	MOG-EAE	Human UCB-MSCs	Basal medium supplemented with B-27, L-glutamin, retinoic acid, bFGF, epidermal growth factor, nerve growth factor, 3-isobutylmethyl-xanthin, and ascorbic acid	5 × 105 UCB-MSCs or MDNPC; i.v. on days 14 and 21 after immunization	↑ clinical score; ↓ leukocyte infiltration	[62]
Female Sprague-Dawley rats	LPC	Rat BM-MSCs	DMEM/F12 with N-2 supplement, B27 supplement, bFGF and epidermal growth factor for 8–12 days	2 × 105; injected into the corpus callosum	↓ demyelination	[63]

bFGF, basic fibroblast growth factor; BM-MSCs, Bone marrow MSCs; EAE, experimental autoimmune encephalomyelitis; IL, interleukin; IFN, Interferon; i.v., intravenous; MOG, myelin oligodendrocyte glycoprotein; MSCs, mesenchymal stem cells; LPC, lysophosphatidylcholine; UCB-MSCs, Umbilical cord blood mesenchymal stromal cells. ↑, enhancement; ↓, reduction.